FDA Expands Marstacimab Indication in Hemophilia A and B - Poll - MDSpire

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor-pretreated populations.

  • By

  • Kathryn Wighton

  • June 8, 2026

  • 3 min

Share

Original Source(s)

FDA Expands Marstacimab Indication in Hemophilia A and B

  • by Kathryn Wighton

  • June 8, 2026

Related Content

Bioabsorbable Implants May Reduce Symptoms in Flatfoot Surgery

Meta-analysis found similar correction with metallic and bioabsorbable devices, but fewer implant-related symptoms with resorbable implants

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.

Not All Lung Bacteria Are the Enemy

Cross-disease meta-analysis also found modest associations with lung function, though findings varied by disease type